ARL14EPL: A Protein with Unique Localization and Functions (G644100)

Target Name: ARL14EPL

NCBI ID: G644100

ARL14EPL

ARL14EPL: A Protein with Unique Localization and Functions

ARL14EPL (loc644100) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is ARL1 (alpha-actinin) 14EPL, and it is a member of the ARL family of proteins that are involved in the regulation of actinin, a protein that is involved in many different cellular processes.

ARL14EPL is unique because of its structure and its location in the body. It is a 21-kDa protein that is expressed in the brain, heart, and kidneys, and it is primarily localized to the endoplasmic reticulum (ER) and the trans-endoplasmic reticulum (TER). The ER is a protein-synthesis shop that retrieves and modifies proteins before they are transported to the TER, where they are translated into functional proteins. The TER is a site of protein synthesis that is involved in the production of a wide variety of proteins, including many involved in cell signaling pathways.

The unique localization of ARL14EPL to the ER and TER is of great interest from a drug-targeting perspective. The ER and TER are often targeted by drugs because they are involved in the production and/or degradation of many proteins, including many involved in diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases. By targeting ARL14EPL, drugs can potentially inhibit its function and disrupt the production of proteins that are involved in these diseases.

In addition to its localization to the ER and TER, ARL14EPL is also unique because of its sequence. It has a unique amino acid sequence that is not found in any other protein, and its sequence is thought to be involved in its function. The unique sequence of ARL14EPL has led to its potential as a drug target.

The specific function of ARL14EPL is not well understood, but it is thought to be involved in the regulation of actinin. Actinin is a protein that is involved in many different cellular processes, including the regulation of cell growth, differentiation, and survival. It is also involved in the regulation of the cytoskeleton, which is the structure that gives cells shape and stability.

In addition to its role in actinin regulation, ARL14EPL is also thought to be involved in the regulation of the cytoskeleton. It is a component of the cytoskeleton, and it is involved in the organization and stability of the cytoskeleton.

The potential drug targets for ARL14EPL are vast. Its unique localization to the ER and TER, combined with its unique amino acid sequence and its involvement in actinin and cytoskeleton regulation, make it an attractive target for drug development.

In conclusion, ARL14EPL is a protein that is expressed in various tissues of the body and is involved in the regulation of actinin and the cytoskeleton. Its unique localization to the ER and TER, combined with its unique amino acid sequence and its involvement in these processes , make it an attractive target for drug development. Further research is needed to fully understand the function of ARL14EPL and its potential as a drug target.

Protein Name: ADP Ribosylation Factor Like GTPase 14 Effector Protein Like

The "ARL14EPL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL14EPL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets